17 February 2021
: Case report
Idiopathic Acquired Hemophilia A, a Rare Cause of Bleeding: A Case Report and Literature Review
Challenging differential diagnosis, Diagnostic / therapeutic accidents, Management of emergency care, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Carlos Andrés Regino1ABCDEFG*, José C. Alvarez1ABCDEFG, Leonardo Mejía Buriticá2ABCDEFG, Natalí Uribe Pulido1ABCDEF, Valeria Torres Yepes3ABCDEFG, José D. Torres24ABCDEFGDOI: 10.12659/AJCR.929401
Am J Case Rep 2021; 22:e929401
Table 4. Guidelines recommendations for treatment of AHA. Modified of references [2,30].
Activated prothrombin complex concentrate (aPCC) | 50–100 U/kg every 8–12 hDo not exceed 200 U/kg/d |
Recombinant FVII activated (rFVIIa) | 70–90 mcg/kg every 2–3 h untilHemostasis achieved |
Recombinant porcine FVIII (rpFVIII) | 200 U/kg initially, titrate according to clinical bleeding and factor VIII activity level |
Corticosteroids | Prednisone 1 mg/kg PO daily |
Corticosteroid and cyclophosphamide | Prednisone 1 mg/kg PO daily, plus cyclophosphamide 1–2 mg/kg PO daily |
Rituximab | Rituximab 375 mg/m IV weekly×4 doses |